These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34159304)

  • 1. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice.
    Boudewijns R; Ma J; Neyts J; Dallmeier K
    JHEP Rep; 2021 Aug; 3(4):100295. PubMed ID: 34159304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.
    Sacherl J; Kosinska AD; Kemter K; Kächele M; Laumen SC; Kerth HA; Öz EA; Wolff LS; Su J; Essbauer S; Sutter G; Scholz M; Singethan K; Altrichter J; Protzer U
    JHEP Rep; 2023 Feb; 5(2):100603. PubMed ID: 36714793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.
    Böcher WO; Dekel B; Schwerin W; Geissler M; Hoffmann S; Rohwer A; Arditti F; Cooper A; Bernhard H; Berrebi A; Rose-John S; Shaul Y; Galle PR; Löhr HF; Reisner Y
    Eur J Immunol; 2001 Jul; 31(7):2071-9. PubMed ID: 11449360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
    King TH; Kemmler CB; Guo Z; Mann D; Lu Y; Coeshott C; Gehring AJ; Bertoletti A; Ho ZZ; Delaney W; Gaggar A; Subramanian GM; McHutchison JG; Shrivastava S; Lee YJ; Kottilil S; Bellgrau D; Rodell T; Apelian D
    PLoS One; 2014; 9(7):e101904. PubMed ID: 25051027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.
    Mudd PA; Piaskowski SM; Neves PC; Rudersdorf R; Kolar HL; Eernisse CM; Weisgrau KL; de Santana MG; Wilson NA; Bonaldo MC; Galler R; Rakasz EG; Watkins DI
    Immunogenetics; 2010 Sep; 62(9):593-600. PubMed ID: 20607226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.
    Ma H; Lim TH; Leerapun A; Weltman M; Jia J; Lim YS; Tangkijvanich P; Sukeepaisarnjaroen W; Ji Y; Le Bert N; Li D; Zhang Y; Hamatake R; Tan N; Li C; Strasser SI; Ding H; Yoon JH; Stace NH; Ahmed T; Anderson DE; Yan L; Bertoletti A; Zhu Q; Yuen MF
    JHEP Rep; 2021 Dec; 3(6):100361. PubMed ID: 34661089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients.
    Wang Q; Sachse P; Semmo M; Lokhande M; Montani M; Dufour JF; Zoulim F; Klenerman P; Semmo N
    J Viral Hepat; 2015 Dec; 22(12):1068-78. PubMed ID: 26075501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus Vector Harboring the HBcAg and Tripeptidyl Peptidase II Genes Induces Potent Cellular Immune Responses In Vivo.
    Tan Q; Ma S; Hu J; Chen X; Yu Y; Tang Z; Zang G
    Cell Physiol Biochem; 2017; 41(2):423-438. PubMed ID: 28214886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Engineered DC-Targeting Lentivector Induces Robust T Cell Responses and Inhibits HBV Replication in HBV Transgenic Mice via Upregulating T Cell Autophagy.
    Ma S; Chen X; Tan Q; Dai S; Li D; Wu S; Yu Y; Zang G; Tang Z
    Cell Physiol Biochem; 2018; 48(3):1041-1059. PubMed ID: 30041239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B.
    Löhr HF; Krug S; Herr W; Weyer S; Schlaak J; Wölfel T; Gerken G; Meyer zum Büschenfelde KH
    Liver; 1998 Dec; 18(6):405-13. PubMed ID: 9869395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques.
    Obeng-Adjei N; Hutnick NA; Yan J; Chu JS; Myles DJ; Morrow MP; Sardesai NY; Weiner DB
    Cancer Gene Ther; 2013 Dec; 20(12):652-62. PubMed ID: 24310062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.
    Dou Y; van Montfoort N; van den Bosch A; de Man RA; Zom GG; Krebber WJ; Melief CJM; Buschow SI; Woltman AM
    J Infect Dis; 2018 Feb; 217(5):827-839. PubMed ID: 29220492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice.
    Horng JH; Lin WH; Wu CR; Lin YY; Wu LL; Chen DS; Chen PJ
    J Biomed Sci; 2020 May; 27(1):70. PubMed ID: 32466788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.
    De Pooter D; Pierson W; Pourshahian S; Dockx K; De Clerck B; Najera I; Davis H; Van Gulck E; Boden D
    Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
    Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
    Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice.
    Zhang Y; Li S; Shan M; Pan X; Zhuang K; He L; Gould K; Tien P
    Immunology; 2007 May; 121(1):105-12. PubMed ID: 17244158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.